Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States
- PMID: 26965532
- DOI: 10.1016/j.jacc.2015.12.054
Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States
Abstract
Background: Transcatheter mitral valve (MV) repair with the MitraClip received approval in 2013 for the treatment of prohibitive-risk patients with primary mitral regurgitation (MR).
Objectives: The aim of this study was to report the initial U.S. commercial experience with transcatheter MV repair.
Methods: Data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry on patients commercially treated with this percutaneous mitral valve repair device were analyzed.
Results: Of 564 patients (56% men, median age 83 years), severe symptoms were present in 473 (86.0%). The median Society of Thoracic Surgeons Predicted Risk of Mortality scores for MV repair and replacement were 7.9% (interquartile range: 4.7% to 12.2%) and 10.0% (interquartile range: 6.3% to 14.5%), respectively. Frailty was noted in 323 patients (57.3%). Transcatheter MV repair was performed for degenerative disease, present in 90.8% of patients. Overall, MR was reduced to grade ≤2 in 93.0%. In-hospital mortality was 2.3%; 30-day mortality was 5.8%. Other 30-day events were stroke (1.8%), bleeding (2.6%), and device-related complications (1.4%). The median length of stay was 3 days (interquartile range: 1 to 6 days), with 84.0% patients discharged home. Overall, procedure success occurred in 90.6%. Variables associated with reduction in MR were end-diastolic dimension, MR severity, clip location, and case volume.
Conclusions: In this study of the initial commercial U.S. experience, it was found that procedural success was achieved in approximately 91% of patients, and the majority of patients were discharged home with moderate or less MR. These data support the effectiveness of this therapy in appropriately selected high-risk patients in a commercial setting. Further study is required to determine the long-term impact of transcatheter MV repair in this patient population.
Keywords: mitral regurgitation; mitral repair; transcatheter.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Commercial Use of MVR: What Have We Learned and What Do We Need to Know?J Am Coll Cardiol. 2016 Mar 15;67(10):1141-1144. doi: 10.1016/j.jacc.2016.01.020. J Am Coll Cardiol. 2016. PMID: 26965533 No abstract available.
Similar articles
-
The Prevalence and Impact of Atrial Fibrillation on 1-Year Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair: Results From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.JACC Cardiovasc Interv. 2019 Mar 25;12(6):569-578. doi: 10.1016/j.jcin.2018.12.012. JACC Cardiovasc Interv. 2019. PMID: 30898255
-
Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II.J Am Coll Cardiol. 2015 Dec 29;66(25):2844-2854. doi: 10.1016/j.jacc.2015.10.018. J Am Coll Cardiol. 2015. PMID: 26718672 Clinical Trial.
-
Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair.J Am Coll Cardiol. 2014 Jul 15;64(2):182-92. doi: 10.1016/j.jacc.2013.10.021. Epub 2013 Oct 31. J Am Coll Cardiol. 2014. PMID: 24184254 Clinical Trial.
-
Current status of transcatheter mitral valve repair therapies - From surgical concepts towards future directions.Scand Cardiovasc J. 2016 Oct-Dec;50(5-6):367-376. doi: 10.1080/14017431.2016.1248482. Epub 2016 Nov 6. Scand Cardiovasc J. 2016. PMID: 27733069 Review.
-
Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium.J Am Coll Cardiol. 2015 Jul 21;66(3):308-321. doi: 10.1016/j.jacc.2015.05.049. J Am Coll Cardiol. 2015. PMID: 26184623
Cited by
-
In-Hospital Outcomes of Transcatheter Tricuspid Valve Repair: An Analysis From the National Inpatient Sample.J Soc Cardiovasc Angiogr Interv. 2022 Aug 4;1(5):100414. doi: 10.1016/j.jscai.2022.100414. eCollection 2022 Sep-Oct. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 39131469 Free PMC article.
-
Modern Perspectives on Hypertrophic Cardiomyopathy-No One Size Fits All.Tex Heart Inst J. 2024 Aug 1;51(2):e248423. doi: 10.14503/THIJ-24-8423. Tex Heart Inst J. 2024. PMID: 39086311 Free PMC article. Review.
-
Transcatheter Edge-to-Edge Repair of Mitral Valve Regurgitation: Closing the Gap to Broaden the Coverage.Rev Cardiovasc Med. 2023 Jan 6;24(1):15. doi: 10.31083/j.rcm2401015. eCollection 2023 Jan. Rev Cardiovasc Med. 2023. PMID: 39076866 Free PMC article. Review.
-
Early Outcomes of Two Large Mitral Valve Transcatheter Edge-to-Edge Repair Devices-A Propensity Score Matched Multicenter Comparison.J Clin Med. 2024 Jul 17;13(14):4187. doi: 10.3390/jcm13144187. J Clin Med. 2024. PMID: 39064227 Free PMC article.
-
Trends in the Management of Anterior Mitral Leaflet Regurgitation.JAMA Netw Open. 2024 Apr 1;7(4):e246726. doi: 10.1001/jamanetworkopen.2024.6726. JAMA Netw Open. 2024. PMID: 38619838 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
